| Detected | Trial | Change |
|---|---|---|
| 2026-06-03 | NCT07011719 Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With… |
Trial sites expanded: 97 -> 118 locations |
| 2026-05-15 | NCT07011719 Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With… |
Trial sites expanded: 44 -> 97 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07641881 A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With… | Metastatic Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT07000149 | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab +… | Advanced Clear Cell Renal Cell Carcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | Renal Cell Carcinoma | Recruiting |
| Phase 1 | |||
| NCT05536141 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma… | Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT07641881 | A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of… | Healthy Participants | Not Yet Recruiting |